Kovac A L, Azad S S, Steer P, Witkowski T, Batenhorst R, McNeal S
Department of Anesthesiology, University of Kansas Medical Center, Kansas City 66160-7415, USA.
J Clin Anesth. 1997 Nov;9(7):532-41. doi: 10.1016/s0952-8180(97)00140-2.
To compare the intraoperative effects and recovery characteristics of remifentanil hydrochloride and alfentanil when administered as part of balanced anesthesia, and to assess the effects of an additional remifentanil infusion administered as analgesic pretreatment before removal of the uterus.
Multicenter, double-blind, randomized, parallel-group study.
Two university hospitals.
35 ASA physical status I, II, and III women scheduled for elective total abdominal hysterectomy with general endotracheal anesthesia.
Patients were premedicated with midazolam 0.05 mg/kg intravenously (i.v.). Anesthesia was induced with thiopental 2 mg/kg, vecuronium 0.15 mg/kg, and a single dose of opioid over 60 seconds (Pump 1): remifentanil 2 micrograms/kg (Remi/Placebo and Remi/Remi groups) or alfentanil 50 micrograms/kg (Alf/Placebo group). Anesthesia was maintained with a nitrous oxide/oxygen mixture (66:34 ratio) and a continuous opioid infusion: remifentanil 0.25 microgram/kg/min (Remi/Placebo and Remi/Remi) or alfentanil 0.5 microgram/kg/min (Alf/Placebo). At skin incision, a second blinded drug infusion was also initiated (Pump 2): remifentanil 0.25 microgram/kg/min (Remi/Remi) or saline placebo (Remi/Placebo and Alf/Placebo). Intraoperative responses were controlled with single doses of opioid and/or rate titrations via Pump 1. Pump 2 was terminated on removal of the uterus. Pump 1 was terminated at skin closure.
The mean (+/- SD) opioid infusion rates administered for the duration of Pump 2 to suppress responses to removal of the uterus were 0.49 +/- 0.27 microgram/kg/min, 1.99 +/- 1.34 micrograms/kg/min, and 0.49 +/- 0.07 microgram/kg/min for the Remi/Placebo, Alf/Placebo, and Remi/Remi groups, respectively. At these rates, similar proportions of patients in the Remi/Placebo (67%) and the Alf/Placebo (60%) groups had responses. Fewer patients had responses in the Remi/Remi group (8%) compared with the Remi/Placebo and Alf/Placebo groups (p < 0.05). The mean total opioid doses used during maintenance were 84.6 micrograms/kg (Remi/Placebo), 393 micrograms/kg (Alf/Placebo), and 68.7 micrograms/kg (Remi/Remi). Awakening times were significantly shorter (p < 0.05) in the remifentanil population compared with the alfentanil population, but discharge times were similar. More patients received naloxone to reverse opioid effects in the alfentanil population (60%) than in the remifentanil population (20%) (p < 0.05).
A mean remifentanil infusion of 0.49 microgram/kg/min is as effective as a mean alfentanil infusion of 1.99 micrograms/kg/min in suppressing intraoperative responses. Doubling of the remifentanil infusion to 0.5 microgram/kg/min before the major stress event improves suppression of responses and lowers intraoperative use of remifentanil without prolonging recovery times. Remifentanil allows faster awakening times than alfentanil, but preemptive administration of postoperative analgesics is recommended to facilitate discharge.
比较盐酸瑞芬太尼和阿芬太尼作为平衡麻醉一部分给药时的术中效果和恢复特征,并评估在子宫切除术前额外输注瑞芬太尼作为镇痛预处理的效果。
多中心、双盲、随机、平行组研究。
两家大学医院。
35例ASA身体状况为I、II和III级、计划行择期全腹子宫切除术并采用全身气管内麻醉的女性。
患者静脉注射咪达唑仑0.05mg/kg进行术前用药。用硫喷妥钠2mg/kg、维库溴铵0.15mg/kg和60秒内单次给予阿片类药物(泵1)诱导麻醉:瑞芬太尼2μg/kg(瑞芬太尼/安慰剂组和瑞芬太尼/瑞芬太尼组)或阿芬太尼50μg/kg(阿芬太尼/安慰剂组)。用氧化亚氮/氧气混合气体(66:34比例)和持续阿片类药物输注维持麻醉:瑞芬太尼0.25μg/kg/min(瑞芬太尼/安慰剂组和瑞芬太尼/瑞芬太尼组)或阿芬太尼0.5μg/kg/min(阿芬太尼/安慰剂组)。在皮肤切开时,还开始第二次盲法药物输注(泵2):瑞芬太尼0.25μg/kg/min(瑞芬太尼/瑞芬太尼组)或生理盐水安慰剂(瑞芬太尼/安慰剂组和阿芬太尼/安慰剂组)。术中反应通过单次给予阿片类药物和/或通过泵1进行速率滴定来控制。子宫切除时泵2停止。皮肤缝合时泵1停止。
为抑制对子宫切除的反应,在泵2持续期间给予的平均(±标准差)阿片类药物输注速率,瑞芬太尼/安慰剂组、阿芬太尼/安慰剂组和瑞芬太尼/瑞芬太尼组分别为0.49±0.27μg/kg/min、1.99±1.34μg/kg/min和0.49±0.07μg/kg/min。以这些速率,瑞芬太尼/安慰剂组(67%)和阿芬太尼/安慰剂组(60%)中出现反应的患者比例相似。与瑞芬太尼/安慰剂组和阿芬太尼/安慰剂组相比,瑞芬太尼/瑞芬太尼组出现反应的患者较少(8%)(p<0.05)。维持期间使用的平均总阿片类药物剂量分别为84.6μg/kg(瑞芬太尼/安慰剂组)、393μg/kg(阿芬太尼/安慰剂组)和68.7μg/kg(瑞芬太尼/瑞芬太尼组)。与阿芬太尼组相比,瑞芬太尼组患者的苏醒时间明显更短(p<0.05),但出院时间相似。与瑞芬太尼组(20%)相比,阿芬太尼组中更多患者接受纳洛酮来逆转阿片类药物的作用(60%)(p<0.05)。
平均瑞芬太尼输注速率0.49μg/kg/min在抑制术中反应方面与平均阿芬太尼输注速率1.99μg/kg/min一样有效。在重大应激事件前将瑞芬太尼输注速率加倍至0.5μg/kg/min可改善对反应的抑制并降低术中瑞芬太尼的使用量,且不延长恢复时间。与阿芬太尼相比,瑞芬太尼能使苏醒时间更快,但建议预防性给予术后镇痛药以促进出院。